Aerie Pharmaceutical (AERI) 39.07 $AERI Biotech
Post# of 273254
Posted On: 09/25/2016 9:15:57 PM
Aerie Pharmaceutical (AERI) 39.07 $AERI
Biotechnology Companies Reaching New Milestones
PR Newswire - Thu Sep 22, 8:00AM CDT
Transparency Market Research published a report on the global biotechnology market and claiming that this vibrant market is expected to grow at an average annual growth rate of CAGR rate of 11.6% by the end of 2017. The data provided indicates that in 2011, the market was valued at roughly $216.5 billion, yet major changes in the way the industry operates and innovative developments in the sector, have pushed values to reach $414.5 billion by the end of 2017. Allergan PLC (NYSE: AGN), Tobira Therapeutics, Inc. (NASDAQ: TBRA), MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), Aerie Pharmaceuticals Inc. (NASDAQ: AERI), Puma Biotechnology Inc. (NYSE: PBYI).
AGN: 243.94 (+0.51), MBVX: 4.72 (-0.04), AERI: 39.07 (+1.02), TBRA: 39.11 (-0.39), PBYI: 68.08 (+2.10)
Company News for September 16, 2016
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 9:10AM CDT
Companies in the News are: GT,AERI,LAKE,ACRX
ACRX: 3.68 (+0.10), GT: 32.30 (-0.12), LAKE: 10.20 (+0.01), AERI: 39.07 (+1.02)
Blog Coverage Aerie Pharma Glaucoma Drug "Roclatan" Surpasses Primary Goals at End Phase III Trials
ACCESSWIRE - Fri Sep 16, 8:16AM CDT
LONDON, UK / ACCESSWIRE / September 16, 2016 / Active Wall St. blog coverage looks at the headline from Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) as the company announced on September 14, 2016, that the Phase III clinical trial results for its eye pressure drug "Roclatan" were positive and achieved its endpoint. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
PFE: 34.26 (+0.11), AERI: 39.07 (+1.02)
Pharma Stock Roundup: Acquisitions & Deals Pick Up Pace, Aerie Up on Positive Data
Arpita Dutt - Zacks Investment Research - Fri Sep 16, 8:04AM CDT
While Bayer (BAYRY) has signed a merger agreement with Monsanto, Allergan will be acquiring Vitae.
AGN: 243.94 (+0.51), PFE: 34.26 (+0.11), AZN: 33.97 (-0.31), AERI: 39.07 (+1.02), TEVA: 51.47 (+0.24), SNY: 38.35 (-0.22)
Aerie Pharmaceuticals Raises $125 Million in Public Offerings
BusinessWire - Fri Sep 16, 5:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the pricing of a registered underwritten public offering of $75 million of shares of its common stock at a price to the public of $29.50 per share, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering was upsized by $25 million over the offering amount anticipated to be sold as previously announced. This is in addition to $50 million raised separately through the completion and full utilization of an at-the-market (ATM) program with Cantor Fitzgerald & Co. filed prior to market open on September 15, 2016. Total gross proceeds raised through these offerings were $125 million. The shares sold through the $50 million ATM program will be issued on or about September 20, 2016, and the $75 million public offering is expected to close on or about September 21, 2016, subject to the satisfaction of customary closing conditions.
AERI: 39.07 (+1.02)
Apple, Goodyear and Noble Energy rise; Wells Fargo slumps
AP - Thu Sep 15, 4:18PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday:
NBL: 33.02 (-1.01), GT: 32.30 (-0.12), GPN: 75.42 (-0.63), AMCX: 52.38 (+1.40), VFC: 56.95 (+0.07), AERI: 39.07 (+1.02), WFC: 45.74 (+0.02), AAPL: 112.71 (-1.91)
Aerie Pharmaceuticals Announces Public Offering of Common Stock
BusinessWire - Thu Sep 15, 3:05PM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that it has commenced a registered underwritten public offering of $50 million of shares of its common stock.
AERI: 39.07 (+1.02)
Aerie (AERI) Stock Up on Positive Phase III Data on Roclatan
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 8:04AM CDT
Aerie (AERI) announced successful 90-day primary efficacy data from a phase III study, Mercury 1, on its eye pressure drug, Roclatan.
ANIP: 66.64 (-0.17), PFE: 34.26 (+0.11), AERI: 39.07 (+1.02), ANIK: 46.92 (-1.07)
Aerie Pharmaceuticals Reports Positive Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results
BusinessWire - Wed Sep 14, 3:01PM CDT
--Conference Call and Webcast Today, September 14, at 5:00 p.m. ET
AERI: 39.07 (+1.02)
Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for Rhopressa(TM) (netarsudil ophthalmic solution) 0.02%
BusinessWire - Tue Sep 06, 3:01PM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Rhopressa(TM) (netarsudil ophthalmic solution) 0.02%. Rhopressa(TM) is a novel once-daily eye drop designed to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The filing includes the results of the first two Phase 3 registration trials for Rhopressa(TM), named Rocket 1 and Rocket 2.
AERI: 39.07 (+1.02)
Aerie (AERI) Q2 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:08AM CDT
Aerie (AERI) posted a wider-than-expected loss of 87 cents in the second-quarter 2016 loss.
AGEN: 6.90 (-0.10), ANIP: 66.64 (-0.17), AERI: 39.07 (+1.02), ANIK: 46.92 (-1.07)
Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
BusinessWire - Thu Aug 04, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the Canaccord Genuity Growth Conference on Wednesday, August 10, 2016 at 12:30 p.m. Eastern Time in Boston, MA. Dr. Anido will provide an Aerie overview and business update.
AERI: 39.07 (+1.02)
Aerie Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Wed Aug 03, 3:01PM CDT
--Mercury 1 Phase 3 Topline Readout for Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Expected in September 2016
AERI: 39.07 (+1.02)
Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:30AM CDT
Can drug stocks Zoetis, Conatus and others pull a surprise when they report their Q2 results on Aug 3?
ZTS: 51.51 (-0.12), JNJ: 118.81 (-0.65), GILD: 81.37 (-0.15), GERN: 2.20 (-0.02), CNAT: 2.11 (-0.05), AERI: 39.07 (+1.02), EXEL: 14.89 (+0.15)
What Awaits Aerie Pharmaceuticals (AERI) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:38PM CDT
Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report second-quarter 2016 results after the market closes on Aug 3.
IPXL: 26.49 (+0.05), IRWD: 15.72 (-0.15), AERI: 39.07 (+1.02), EXEL: 14.89 (+0.15)
Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of Rhopressa(TM)(netarsudil ophthalmic solution) 0.02%
BusinessWire - Thu Jun 16, 5:30AM CDT
---Rocket 4 Designed for EU Filing; Not Required for US NDA Filing-
AERI: 39.07 (+1.02)
Aerie Pharmaceuticals to Participate in Two Investor Conferences in June
BusinessWire - Thu Jun 02, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that company management will present an overview of the company at the following conferences in June.
AERI: 39.07 (+1.02)
Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of Roclatan(TM)(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
BusinessWire - Thu May 05, 5:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced the completion of patient enrollment in the Company's initial Phase 3 registration trial ("Mercury 1"
of Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Roclatan(TM) is a fixed dose combination of Aerie drug Rhopressa(TM) (netarsudil ophthalmic solution) 0.02% and latanoprost, the most widely prescribed PGA (prostaglandin analogue). Mercury 1 has total enrollment of approximately 690 patients in this three-arm study, designed to demonstrate superiority of Roclatan(TM) to each of its two components, all dosed once daily in the evening. The range for the primary endpoint evaluates patients with maximum baseline IOPs ranging from above 20 to below 36 mmHg (millimeters of mercury). Mercury 1, which commenced in September 2015 is a twelve-month safety trial with a 90-day interim efficacy readout that is expected in the third quarter of 2016. In March 2016, the Company commenced a second Phase 3 registration trial for Roclatan(TM), Mercury 2, which is a 90-day efficacy trial, and also plans to commence in the first half of 2017 a third Phase 3 clinical trial for Roclatan(TM), named Mercury 3, which will be designed to facilitate regulatory approval and commercialization in Europe.
AERI: 39.07 (+1.02)
Aerie Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
BusinessWire - Wed May 04, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Wednesday, May 11, 2016 at 3:00 p.m. Pacific Time in Las Vegas, NV. Dr. Anido will provide an Aerie overview and business update.
AERI: 39.07 (+1.02)
Biotechnology Companies Reaching New Milestones
PR Newswire - Thu Sep 22, 8:00AM CDT
Transparency Market Research published a report on the global biotechnology market and claiming that this vibrant market is expected to grow at an average annual growth rate of CAGR rate of 11.6% by the end of 2017. The data provided indicates that in 2011, the market was valued at roughly $216.5 billion, yet major changes in the way the industry operates and innovative developments in the sector, have pushed values to reach $414.5 billion by the end of 2017. Allergan PLC (NYSE: AGN), Tobira Therapeutics, Inc. (NASDAQ: TBRA), MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), Aerie Pharmaceuticals Inc. (NASDAQ: AERI), Puma Biotechnology Inc. (NYSE: PBYI).
AGN: 243.94 (+0.51), MBVX: 4.72 (-0.04), AERI: 39.07 (+1.02), TBRA: 39.11 (-0.39), PBYI: 68.08 (+2.10)
Company News for September 16, 2016
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 9:10AM CDT
Companies in the News are: GT,AERI,LAKE,ACRX
ACRX: 3.68 (+0.10), GT: 32.30 (-0.12), LAKE: 10.20 (+0.01), AERI: 39.07 (+1.02)
Blog Coverage Aerie Pharma Glaucoma Drug "Roclatan" Surpasses Primary Goals at End Phase III Trials
ACCESSWIRE - Fri Sep 16, 8:16AM CDT
LONDON, UK / ACCESSWIRE / September 16, 2016 / Active Wall St. blog coverage looks at the headline from Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) as the company announced on September 14, 2016, that the Phase III clinical trial results for its eye pressure drug "Roclatan" were positive and achieved its endpoint. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
PFE: 34.26 (+0.11), AERI: 39.07 (+1.02)
Pharma Stock Roundup: Acquisitions & Deals Pick Up Pace, Aerie Up on Positive Data
Arpita Dutt - Zacks Investment Research - Fri Sep 16, 8:04AM CDT
While Bayer (BAYRY) has signed a merger agreement with Monsanto, Allergan will be acquiring Vitae.
AGN: 243.94 (+0.51), PFE: 34.26 (+0.11), AZN: 33.97 (-0.31), AERI: 39.07 (+1.02), TEVA: 51.47 (+0.24), SNY: 38.35 (-0.22)
Aerie Pharmaceuticals Raises $125 Million in Public Offerings
BusinessWire - Fri Sep 16, 5:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the pricing of a registered underwritten public offering of $75 million of shares of its common stock at a price to the public of $29.50 per share, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering was upsized by $25 million over the offering amount anticipated to be sold as previously announced. This is in addition to $50 million raised separately through the completion and full utilization of an at-the-market (ATM) program with Cantor Fitzgerald & Co. filed prior to market open on September 15, 2016. Total gross proceeds raised through these offerings were $125 million. The shares sold through the $50 million ATM program will be issued on or about September 20, 2016, and the $75 million public offering is expected to close on or about September 21, 2016, subject to the satisfaction of customary closing conditions.
AERI: 39.07 (+1.02)
Apple, Goodyear and Noble Energy rise; Wells Fargo slumps
AP - Thu Sep 15, 4:18PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday:
NBL: 33.02 (-1.01), GT: 32.30 (-0.12), GPN: 75.42 (-0.63), AMCX: 52.38 (+1.40), VFC: 56.95 (+0.07), AERI: 39.07 (+1.02), WFC: 45.74 (+0.02), AAPL: 112.71 (-1.91)
Aerie Pharmaceuticals Announces Public Offering of Common Stock
BusinessWire - Thu Sep 15, 3:05PM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that it has commenced a registered underwritten public offering of $50 million of shares of its common stock.
AERI: 39.07 (+1.02)
Aerie (AERI) Stock Up on Positive Phase III Data on Roclatan
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 8:04AM CDT
Aerie (AERI) announced successful 90-day primary efficacy data from a phase III study, Mercury 1, on its eye pressure drug, Roclatan.
ANIP: 66.64 (-0.17), PFE: 34.26 (+0.11), AERI: 39.07 (+1.02), ANIK: 46.92 (-1.07)
Aerie Pharmaceuticals Reports Positive Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results
BusinessWire - Wed Sep 14, 3:01PM CDT
--Conference Call and Webcast Today, September 14, at 5:00 p.m. ET
AERI: 39.07 (+1.02)
Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for Rhopressa(TM) (netarsudil ophthalmic solution) 0.02%
BusinessWire - Tue Sep 06, 3:01PM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Rhopressa(TM) (netarsudil ophthalmic solution) 0.02%. Rhopressa(TM) is a novel once-daily eye drop designed to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The filing includes the results of the first two Phase 3 registration trials for Rhopressa(TM), named Rocket 1 and Rocket 2.
AERI: 39.07 (+1.02)
Aerie (AERI) Q2 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:08AM CDT
Aerie (AERI) posted a wider-than-expected loss of 87 cents in the second-quarter 2016 loss.
AGEN: 6.90 (-0.10), ANIP: 66.64 (-0.17), AERI: 39.07 (+1.02), ANIK: 46.92 (-1.07)
Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
BusinessWire - Thu Aug 04, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the Canaccord Genuity Growth Conference on Wednesday, August 10, 2016 at 12:30 p.m. Eastern Time in Boston, MA. Dr. Anido will provide an Aerie overview and business update.
AERI: 39.07 (+1.02)
Aerie Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Wed Aug 03, 3:01PM CDT
--Mercury 1 Phase 3 Topline Readout for Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Expected in September 2016
AERI: 39.07 (+1.02)
Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:30AM CDT
Can drug stocks Zoetis, Conatus and others pull a surprise when they report their Q2 results on Aug 3?
ZTS: 51.51 (-0.12), JNJ: 118.81 (-0.65), GILD: 81.37 (-0.15), GERN: 2.20 (-0.02), CNAT: 2.11 (-0.05), AERI: 39.07 (+1.02), EXEL: 14.89 (+0.15)
What Awaits Aerie Pharmaceuticals (AERI) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:38PM CDT
Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report second-quarter 2016 results after the market closes on Aug 3.
IPXL: 26.49 (+0.05), IRWD: 15.72 (-0.15), AERI: 39.07 (+1.02), EXEL: 14.89 (+0.15)
Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of Rhopressa(TM)(netarsudil ophthalmic solution) 0.02%
BusinessWire - Thu Jun 16, 5:30AM CDT
---Rocket 4 Designed for EU Filing; Not Required for US NDA Filing-
AERI: 39.07 (+1.02)
Aerie Pharmaceuticals to Participate in Two Investor Conferences in June
BusinessWire - Thu Jun 02, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that company management will present an overview of the company at the following conferences in June.
AERI: 39.07 (+1.02)
Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of Roclatan(TM)(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
BusinessWire - Thu May 05, 5:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced the completion of patient enrollment in the Company's initial Phase 3 registration trial ("Mercury 1"
of Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Roclatan(TM) is a fixed dose combination of Aerie drug Rhopressa(TM) (netarsudil ophthalmic solution) 0.02% and latanoprost, the most widely prescribed PGA (prostaglandin analogue). Mercury 1 has total enrollment of approximately 690 patients in this three-arm study, designed to demonstrate superiority of Roclatan(TM) to each of its two components, all dosed once daily in the evening. The range for the primary endpoint evaluates patients with maximum baseline IOPs ranging from above 20 to below 36 mmHg (millimeters of mercury). Mercury 1, which commenced in September 2015 is a twelve-month safety trial with a 90-day interim efficacy readout that is expected in the third quarter of 2016. In March 2016, the Company commenced a second Phase 3 registration trial for Roclatan(TM), Mercury 2, which is a 90-day efficacy trial, and also plans to commence in the first half of 2017 a third Phase 3 clinical trial for Roclatan(TM), named Mercury 3, which will be designed to facilitate regulatory approval and commercialization in Europe. AERI: 39.07 (+1.02)
Aerie Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
BusinessWire - Wed May 04, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Wednesday, May 11, 2016 at 3:00 p.m. Pacific Time in Las Vegas, NV. Dr. Anido will provide an Aerie overview and business update.
AERI: 39.07 (+1.02)
(0)
(0)Scroll down for more posts ▼